» Articles » PMID: 28054314

Turning Back the Wheel: Inducing Mesenchymal to Epithelial Transition Via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis

Overview
Specialty Oncology
Date 2017 Jan 6
PMID 28054314
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from the surface of the pleura and is associated with a history of asbestos exposure. The tumor is characterized by a strong local invasiveness and a poor response to any single modality therapy. Therefore clinical outcome of patients with MPM is poor and median survival time of untreated patients with MPM is 7 months from initial diagnosis. The Wilms Tumor Protein 1 (WT1) is a transcription factor which is highly expressed by MPM and is involved in cellular development and survival. We evaluated the role of WT1 in two human MPM cell lines (MSTO and H2052) expressing high levels of WT1. We performed a knockdown of WT1 using siRNA. Knockdown of WT1 was confirmed by Westernblotting. After knockdown of WT1 we investigated the effect on proliferation, chemoresistance, chemotaxis and migration. We could demonstrate that knockdown of WT1 suppresses chemoresistance in both cell lines compared with control (scrambled siRNA). Additionally, WT1 knockdown reduces proliferation, chemotaxis and invasiveness of mesothelioma cell lines. WT1 reduces malignancy of malignant mesothelioma cell lines and might be a new molecular target in mesothelioma therapy. Further investigations are needed to discover the mechanisms of chemoresistance depending on WT1.

Citing Articles

Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors.

Chang M, Matnurov E, Wu C, Arakelyan J, Choe H, Kushnarev V J Am Chem Soc. 2025; 147(9):7908-7920.

PMID: 39992709 PMC: 11887451. DOI: 10.1021/jacs.4c17966.


Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy.

Nian Q, Lin Y, Zeng J, Zhang Y, Liu R Transl Oncol. 2024; 52():102237.

PMID: 39672002 PMC: 11700300. DOI: 10.1016/j.tranon.2024.102237.


Chemosensitivity of three patient-derived primary cultures of canine pericardial mesothelioma by single-agent and combination treatment.

Nabeta R, Kanaya A, Elbadawy M, Usui T, Furuya T, Suzuki K Front Vet Sci. 2023; 10:1267359.

PMID: 38026668 PMC: 10653591. DOI: 10.3389/fvets.2023.1267359.


Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.

Offin M, Sauter J, Tischfield S, Egger J, Chavan S, Shah N Genome Med. 2022; 14(1):127.

PMID: 36380343 PMC: 9667652. DOI: 10.1186/s13073-022-01129-4.


WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease.

Lee W, Chiu C, Chu T, Chien Y Front Cell Dev Biol. 2022; 10:876723.

PMID: 35465313 PMC: 9019781. DOI: 10.3389/fcell.2022.876723.


References
1.
Hohenstein P, Hastie N . The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006; 15 Spec No 2:R196-201. DOI: 10.1093/hmg/ddl196. View

2.
Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S . Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer. 2002; 100(3):297-303. DOI: 10.1002/ijc.10476. View

3.
Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

4.
Merritt N, Blewett C, Miller J, Bennett W, Young J, Urschel J . Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol. 2001; 78(3):171-4. DOI: 10.1002/jso.1143. View

5.
Zamora-Avila D, Franco-Molina M, Trejo-Avila L, Rodriguez-Padilla C, Resendez-Perez D, Zapata-Benavides P . RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res. 2007; 17(6):341-8. DOI: 10.1097/CMR.0b013e3282efd3ae. View